CN114845705A - 用于治疗胃肠疾病的口服固体大麻素油组合物 - Google Patents

用于治疗胃肠疾病的口服固体大麻素油组合物 Download PDF

Info

Publication number
CN114845705A
CN114845705A CN202180007577.3A CN202180007577A CN114845705A CN 114845705 A CN114845705 A CN 114845705A CN 202180007577 A CN202180007577 A CN 202180007577A CN 114845705 A CN114845705 A CN 114845705A
Authority
CN
China
Prior art keywords
cannabinoid oil
oil
microcrystalline cellulose
cannabinoid
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180007577.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·沙阿
F·哈桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Publication of CN114845705A publication Critical patent/CN114845705A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202180007577.3A 2020-01-08 2021-01-08 用于治疗胃肠疾病的口服固体大麻素油组合物 Pending CN114845705A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958392P 2020-01-08 2020-01-08
US62/958,392 2020-01-08
PCT/EP2021/050245 WO2021140183A1 (en) 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Publications (1)

Publication Number Publication Date
CN114845705A true CN114845705A (zh) 2022-08-02

Family

ID=74236138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180007577.3A Pending CN114845705A (zh) 2020-01-08 2021-01-08 用于治疗胃肠疾病的口服固体大麻素油组合物

Country Status (8)

Country Link
US (2) US12186281B2 (https=)
EP (1) EP4087547A1 (https=)
JP (1) JP2023509675A (https=)
CN (1) CN114845705A (https=)
AU (1) AU2021206021A1 (https=)
BR (1) BR112022010335A2 (https=)
CA (1) CA3164489A1 (https=)
WO (1) WO2021140183A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021417405A1 (en) * 2021-01-08 2023-06-22 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating central nervous system disorders
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017325A1 (en) * 2011-02-11 2014-01-16 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CN103796637A (zh) * 2011-07-05 2014-05-14 韦特股份有限公司 大麻素受体结合剂、组合物以及方法
US20180078504A1 (en) * 2016-02-11 2018-03-22 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用
CN109152748A (zh) * 2016-05-06 2019-01-04 哈维斯特·迪莱科特企业有限公司 口服大麻药物的制造方法、组合物和医学应用
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
CN109789095A (zh) * 2016-07-25 2019-05-21 Ebbu 公司 新的大麻片剂配方和组合物及其制造方法
JP2019530717A (ja) * 2016-10-12 2019-10-24 コロンビア ケア エルエルシー 抽出されたカンナビノイドの経口組成物およびその使用の方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012109216A1 (en) * 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
CA2909591C (en) * 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US20190091198A1 (en) * 2016-03-28 2019-03-28 Lihi BAR-LEV SCHLEIDER Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
CA3078549A1 (en) * 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
WO2019234743A1 (en) 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017325A1 (en) * 2011-02-11 2014-01-16 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CN103796637A (zh) * 2011-07-05 2014-05-14 韦特股份有限公司 大麻素受体结合剂、组合物以及方法
US20180078504A1 (en) * 2016-02-11 2018-03-22 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
CN109152748A (zh) * 2016-05-06 2019-01-04 哈维斯特·迪莱科特企业有限公司 口服大麻药物的制造方法、组合物和医学应用
CN109789095A (zh) * 2016-07-25 2019-05-21 Ebbu 公司 新的大麻片剂配方和组合物及其制造方法
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
JP2019530717A (ja) * 2016-10-12 2019-10-24 コロンビア ケア エルエルシー 抽出されたカンナビノイドの経口組成物およびその使用の方法
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
冯日露 等: "糖尿病胃轻瘫的发病机制、诊断和治疗研究进展", 上海交通大学学报（医学版）, vol. 36, no. 5, pages 761 - 766 *

Also Published As

Publication number Publication date
US20210205235A1 (en) 2021-07-08
US12186281B2 (en) 2025-01-07
US11717494B2 (en) 2023-08-08
BR112022010335A2 (pt) 2022-08-16
JP2023509675A (ja) 2023-03-09
WO2021140183A1 (en) 2021-07-15
CA3164489A1 (en) 2021-07-15
US20230065736A1 (en) 2023-03-02
AU2021206021A1 (en) 2022-06-02
EP4087547A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP6105761B2 (ja) 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
CN103442727B (zh) 多微粒l-薄荷醇制剂及相关方法
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
BG65443B1 (bg) Ентерично покрит фармацевтичен състав, съдържащ диданозин
JP2004501099A (ja) アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
CN109310642B (zh) 美沙拉嗪的口服药物组合物
JP2014501267A (ja) メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US12186281B2 (en) Oral solid cannabinoid oil composition for treating gastrointestinal disorders
US11207276B2 (en) Multiparticulate L-menthol formulations and related methods
WO2020227437A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
EP0876142B1 (en) Topical delivery of drugs to the lower gastrointestinal tract
CN109152772B (zh) 烟酰胺的口服药物组合物
WO2021001860A1 (en) Pharmaceutical compositions of boswellia serrata
CN116546983A (zh) 用于治疗中枢神经系统疾病的口服固体大麻素油组合物
Singh et al. Development of biphasic pulsatile release mini-tablets system of poorly water soluble carvedilol phosphate
JP2000503658A (ja) 下部胃腸管への薬剤の局所送達

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220802

RJ01 Rejection of invention patent application after publication